Cover Image
市場調查報告書

停經後陰道萎縮症治療藥的全球市場:2016∼2020年

Global Post Menopausal Vaginal Atrophy Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 356730
出版日期 內容資訊 英文 69 Pages
訂單完成後即時交付
價格
Back to Top
停經後陰道萎縮症治療藥的全球市場:2016∼2020年 Global Post Menopausal Vaginal Atrophy Drugs Market 2016-2020
出版日期: 2016年04月12日 內容資訊: 英文 69 Pages
簡介

陰道萎縮症也稱為萎縮性陰道炎,停經後的女性最大40%患該症狀。治療有荷爾蒙置換療法和雌激素軟膏等使用。全球停經後陰道萎縮症治療藥市場,預計2016∼2020年,以年複合成長率7.13%擴大。

本報告提供全球停經後陰道萎縮症治療藥市場現狀與至2020年的成長預測,市場趨勢與課題,各地區趨勢,主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 概要:停經後陰道萎縮症

  • 症狀
  • 原因
  • 病理學
  • 診斷
  • 治療
  • 流行病學

第6章 品牌藥簡介

第7章 市場情況

  • 市場概要
  • 市場規模與預測

第8章 藥物場市場區隔

  • 局部用雌激素
  • 全身用雌激素

第9章 各地區市場區隔

  • 南北美洲
  • 美國
  • 歐洲、中東、非洲
  • 歐洲
  • 亞太地區
  • 日本

第10章 推動市場的要素

第11章 促進要素的影響

第12章 市場課題

第13章 促進要素與課題的影響

第14章 市場趨勢

第15章 供應商環境

  • 競爭模式
  • 市場佔有率分析:2015年
  • Pfizer
  • Allergan
  • 鹽野義製藥株式會社
  • Novo Nordisk
  • Teva Pharmaceutical
  • 其他值得注意的供應商

第16章 附錄

第17章 關於Technavio

圖表

目錄
Product Code: IRTNTR8969

About Post-Menopausal Vaginal Atrophy Drugs

Vaginal atrophy also known as atrophic vaginitis is defined as a decrease in the production of estrogen after menopause, leading to thinning, drying, and reduced elasticity of the vaginal tissues. Up to 40% of post-menopausal women have symptoms of atrophic vaginitis. It typically affects women in the age group of 45-55 years. PVA result in symptoms such as itching, burning, dryness, and dyspareunia. Topical preparations such as hormone replacement therapy (HRT) and estrogen creams are used to treat PVA.

Technavio's analysts forecast the global PVA drugs market to grow at a CAGR of 7.13% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global PVA drugs market for 2015-2020. To calculate the market size, the report considers revenue generated from the sales of drugs (creams, tablets, patches, and rings) used to treat PVA.

The market is divided into the following segments based on geography:

  • Americas
  • EMEA
  • APAC

Technavio's report, Global Post-Menopausal Vaginal Atrophy Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Pfizer Inc.
  • Allergan Inc.
  • Shionogi & Co. Ltd.
  • Novo Nordisk A/S
  • Teva Pharmaceutical Industries Ltd.

Other Prominent Vendors

  • Bayer
  • Bionovo
  • EndoCeutics
  • Foamix Pharmaceuticals
  • Ligand Pharmaceuticals
  • Pantarhei Bioscience
  • Pep-Tonic Medical
  • TherapeuticsMD
  • Upsher-Smith Laboratories

Market driver

  • Favorable healthcare reforms in the US
  • For a full, detailed list, view our report

Market challenge

  • Patent expiry of branded products
  • For a full, detailed list, view our report

Market trend

  • Paradigm shift to non-estrogenic therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings
  • Assumptions

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Key buying criteria

PART 05: Overview: Vaginal atrophy

  • Symptoms
  • Causes
  • Pathophysiology
  • Diagnosis
  • Treatment
  • Epidemiology

PART 06: Branded drug profiles

  • Activella
  • Enjuvia
  • Estrace
  • Femring
  • Premarin
  • Osphena
  • Vagifem

PART 07: Market landscape

  • Market overview
  • Market size and forecast

PART 08: Market segmentation by drug class

  • Topical estrogen
  • Systemic estrogen

PART 09: Geographical segmentation

  • Global PVA drugs market by geographical segmentation 2015-2020
  • PVA drugs market in Americas
  • PVA drugs market in US
  • PVA drugs market in EMEA
  • PVA drugs market in Europe
  • PVA drugs market in APAC
  • PVA drugs market in Japan

PART 10: Market drivers

  • Significant unmet medical needs
  • Favorable healthcare reforms in US
  • Increase in awareness of PVA
  • Cost-effective OTC drugs

PART 11: Impact of drivers

PART 12: Market challenges

  • Patent expiry of branded products
  • Low diagnosis rates
  • Poor patient adherence
  • Side effects of drugs

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Paradigm shift to non-estrogenic therapies
  • Increased R&D
  • Patient assistance programs
  • Strategic alliances

PART 15: Vendor landscape

  • Competitive scenario
  • Market share analysis 2015
  • Pfizer
  • Allergan
  • Shionogi
  • Novo Nordisk
  • Teva Pharmaceutical
  • Other prominent vendors

PART 16: Appendix

  • List of abbreviations

PART 17: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key buying criteria for PVA drugs
  • Exhibit 03: Symptoms of PVA
  • Exhibit 04:
  • Exhibit 05: Percentage of major vaginal atrophy symptoms in postmenopausal women
  • Exhibit 06: Causes of PVA
  • Exhibit 07: Effects of estrogen deficiency
  • Exhibit 08: Treatment for PVA
  • Exhibit 09: Some hormonal treatments for PVA
  • Exhibit 10: Top concerns associated with OTC lubricants or moisturizers for PVA
  • Exhibit 11: Top concerns about use of vaginal estrogen for PVA
  • Exhibit 12: Prevalence of vaginal atrophy symptoms in postmenopausal women by country 2014
  • Exhibit 13: Global PVA drugs market 2015-2020 ($ billions)
  • Exhibit 14: Five forces analysis
  • Exhibit 15: Global PVA drugs market segmentation by drug class
  • Exhibit 16: Global PVA drugs market share by drug class
  • Exhibit 17: Preference for oral or vaginal ROA by age 2014
  • Exhibit 18: Global PVA drugs market by geography 2015
  • Exhibit 19: Global PVA drugs market revenue by geography 2015-2020 ($ millions)
  • Exhibit 20: Global PVA drugs market: YoY revenue and growth based on geography 2015-2020 ($ millions)
  • Exhibit 21: PVA drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 22: PVA drugs market in Americas by country 2015
  • Exhibit 23: PVA drugs market in US 2015-2020 ($ billions)
  • Exhibit 24: Share of PVA drugs in US by drug class 2015
  • Exhibit 25: PVA drugs market in EMEA 2015-2020 ($ millions)
  • Exhibit 26: PVA drugs market in EMEA by region 2015
  • Exhibit 27: PVA drugs market in Europe 2015-2020 ($ millions)
  • Exhibit 28: Share of PVA drugs in Europe by drug class 2015
  • Exhibit 29: PVA drugs market in APAC 2015-2020 ($ millions)
  • Exhibit 30: PVA drugs market in APAC by country 2015
  • Exhibit 31: PVA drugs market in Japan 2015-2020 ($ millions)
  • Exhibit 32: Share of PVA drugs in Japan by drug class 2015
  • Exhibit 33: Specific OTC treatments for vaginal atrophy
  • Exhibit 34: Impact of drivers
  • Exhibit 35: Impact of drivers and challenges
  • Exhibit 36: Global PVA drugs market share analysis 2015
  • Exhibit 37: Market share analysis of top vendors 2015
  • Exhibit 38: Timeline and history of Premarin
  • Exhibit 39: Pfizer: YoY revenue and growth rate of Premarin 2013-2015 ($ billions)
  • Exhibit 40: Pfizer: Geographical segmentation of Premarin 2015
  • Exhibit 41: Pfizer: Key takeaways
  • Exhibit 42: Allergan: YoY revenue and growth rate of Estrace 2013-2015 ($ millions)
  • Exhibit 43: Allergan: Key takeaways
  • Exhibit 44: YoY revenue comparison of Osphena 2013 and 2014 ($ millions)
  • Exhibit 45: Shionogi: Key takeaways
  • Exhibit 46: Novo Nordisk: Key takeaways
  • Exhibit 47: Timeline for Enjuvia
  • Exhibit 48: Teva Pharmaceutical: Key takeaways
Back to Top